RespireRx Pharmaceuticals Overview

  • Founded
  • 1987

Founded
  • Status
  • Public

  • Employees
  • 2

Employees
  • Stock Symbol
  • RSPI

Stock Symbol
  • Investments
  • 1

RespireRx Pharmaceuticals General Information

Description

RespireRx Pharmaceuticals Inc is engaged in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is developed for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; CX1739 for the treatment of chronic central sleep apnea; CX717 and CX1942 is an injectable dosage for respiratory depression or vaso-occlusive passes associated with sickle cell disease. The company also focuses on developing another class of compounds called ampakines for the treatment of various respiratory disorders.

Contact Information

Formerly Known As
Cortex Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
PINX
Primary Office
  • 126 Valley Road
  • Suite C
  • Glen Rock, NJ 07452
  • United States
+1 (917) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

RespireRx Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$349K 103M 565K -$0.04

RespireRx Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 2,826 2,987 3,539 1,953
Revenue 0 0 0 0
EBITDA (2,250) (2,420) (3,756) (1,710)
Net Income (3,155) (3,145) (4,301) (2,115)
Total Assets 103 209 85 45
Total Debt 2,439 2,078 1,684 1,634
Public Fundamental Data provided by Morningstar, Inc. disclaimer

RespireRx Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore RespireRx Pharmaceuticals‘s full profile, request access.

Request a free trial

RespireRx Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
RespireRx Pharmaceuticals Inc is engaged in the discovery, development, and commercialization of pharmaceuticals for the
Pharmaceuticals
Glen Rock, NJ
2 As of 2021
00.000
000000000 00.000

000000

didunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco
000000000000000
Cambridge, MA
000 As of 0000
00000
000000000 00000

000000

dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut ali
0000 000000000
Boston, MA
0000 As of 0000
00.000
000 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

RespireRx Pharmaceuticals Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ironwood Pharmaceuticals Formerly VC-backed Cambridge, MA 000 00000 000000000 00000
000000 00000000000 Formerly VC-backed Boston, MA 0000 00.000 000000&0
00000 000000000000 Corporate Backed or Acquired Carlsbad, CA 000 0000 00000000000 0000
You’re viewing 3 of 3 competitors. Get the full list »

RespireRx Pharmaceuticals Patents

RespireRx Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20100286177-A1 Bicyclic amides for the treatment of respiratory depression Granted 10-Aug-2007 000000000
US-20130190351-A1 Bicyclic amides for enhancing glutamatergic synaptic responses Granted 10-Aug-2007 000000000
US-20110003835-A1 Methods for the treatment of respiratory depression Granted 10-Aug-2007 000000000 0
US-9492440-B2 Bicyclic amides for enhancing glutamatergic synaptic responses Active 10-Aug-2007 000000000 0
US-8110584-B2 Methods for the treatment of respiratory depression Expired - Fee Related 10-Aug-2007 A61K31/46 0
To view RespireRx Pharmaceuticals’s complete patent history, request access »

RespireRx Pharmaceuticals Executive Team (7)

Name Title Board Seat Contact Info
Jeff Margolis Chief Financial Officer, Senior Vice President, Secretary, Treasurer & Board Member
Arnold Lippa Ph.D Executive Chairman, Chief Scientific Officer, Interim President & Interim Chief Executive Officer
You’re viewing 2 of 7 executive team members. Get the full list »

RespireRx Pharmaceuticals Board Members (11)

Name Representing Role Since
000000 00000 00.0 Self Executive Chairman, Chief Scientific Officer, Interim President & Interim Chief Executive Officer 000 0000
0000000 000000000 Self Board Member 000 0000
00000 0000000000 Self Director 000 0000
0000000 0000000000 Self Director 000 0000
00000 00000 00.0 RespireRx Pharmaceuticals Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

RespireRx Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

RespireRx Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore RespireRx Pharmaceuticals‘s full profile, request access.

Request a free trial

RespireRx Pharmaceuticals Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 00000000 14-Aug-2012 0000000000 00.000 Pharmaceuticals
To view RespireRx Pharmaceuticals’s complete acquisitions history, request access »